FDA strengthens metformin labelling: annual vitamin B12 monitoring now explicitly recommended for all patients on long-term therapy
FDA has updated prescribing information for all metformin-containing products to explicitly recommend annual serum vitamin B12 measurement in all patients on long-term metformin therapy (>12 months), not only those with peripheral neuropathy or anaemia. The revision follows a post-marketing pharmacoepidemiology review confirming that metformin reduces vitamin B12 absorption by competing with calcium-dependent intrinsic factor in the terminal ileum, with deficiency prevalence of 10–30% in long-term users. Calcium supplementation may partially mitigate this effect. The label now specifies that B12 deficiency can manifest as peripheral neuropathy that may be misattributed to diabetic neuropathy.
On 18 October 2026, FDA updated prescribing information for all metformin-containing products — metformin IR, metformin ER (Glucophage XR), and combination products (metformin/sitagliptin, metformin/empagliflozin, etc.) — to explicitly recommend annual serum vitamin B12 measurement for all patients on long-term therapy (>12 months), regardless of symptoms. Previously the label recommended periodic monitoring "in predisposed patients," which was widely interpreted to mean only those with neuropathy or anaemia. Updated labels are available on DailyMed ↗. This is a class-wide update affecting branded and generic metformin.
Mechanism: how metformin depletes vitamin B12
Metformin reduces vitamin B12 absorption in the terminal ileum via a calcium-dependent mechanism. Vitamin B12 absorption requires binding to intrinsic factor (IF, produced by gastric parietal cells) to form the B12-IF complex, which then binds calcium-dependent receptors (cubilin/amnionless) in ileal enterocytes. Metformin competitively interferes with calcium-dependent uptake at this step. Calcium supplementation (≥1,200 mg/day) has been shown in clinical studies to partially reverse metformin-induced B12 malabsorption — Bauman et al. 2000 (PubMed) ↗. The label update therefore also mentions that calcium supplementation may be considered. See our drug metabolism guide for broader context on drug-nutrient interactions.
Prevalence, clinical consequences, and who is at highest risk
Metformin-associated B12 deficiency affects approximately 10–30% of long-term users (duration >5 years). A 2019 meta-analysis of 28 studies in Diabetes Care (PubMed) ↗ found a pooled OR of 2.09 (95% CI 1.83–2.39) for B12 deficiency vs non-metformin-treated diabetes patients. Critically, B12-deficiency peripheral neuropathy is clinically indistinguishable from diabetic peripheral neuropathy — creating a risk that patients are overtreated for diabetic neuropathy rather than the reversible B12 deficiency. Highest-risk patients: elderly, vegetarian/vegan diet, previous gastric surgery, concurrent use of proton pump inhibitors, chronic kidney disease (impaired cubilin expression). See our renal dosing guide for metformin CKD dose limits.
Monitoring protocol and treatment of deficiency
The updated label recommends: serum B12 at baseline, then annually. Threshold for action: serum B12 <300 pmol/L warrants supplementation; <200 pmol/L (deficiency) warrants higher-dose supplementation and clinical assessment for neuropathy. For patients with neuropathy, measure methylmalonic acid (MMA) and homocysteine as more sensitive markers of functional B12 deficiency. Treatment: oral cyanocobalamin 1,000–2,000 mcg/day (effective even in malabsorption at pharmacological doses via passive diffusion) or IM hydroxocobalamin. Metformin dose reduction is typically not indicated solely for B12 monitoring — the cardiovascular and glycaemic benefits of metformin are established in NICE NG28 type 2 diabetes guidelines ↗ and ADA Standards of Care ↗. Report adverse events to FDA MedWatch ↗.
FAQ
What triggers an FDA label update?
Label updates can be triggered by post-market safety data from the FAERS database ↗, new clinical trial results, manufacturer-initiated reviews, or FDA-directed safety communications. The FDA can require label changes under 21 CFR 314.81 or negotiate them with manufacturers. See the FDA Safety-related Labeling Changes (SrLC) database ↗ for a full history.
Where is the updated label published?
Updated labels are published on DailyMed (NLM) ↗ and Drugs@FDA ↗. DailyMed is typically the most current source, as manufacturers submit label updates there directly.